ARTICLE

The expanding spectrum of *COL2A1* gene variants IN 136 patients with a skeletal dysplasia phenotype

Mouna Barat-Houari^{*,1,2}, Bruno Dumont¹, Aurélie Fabre¹, Frédéric TM Them³, Yves Alembik⁴, Jean-Luc Alessandri⁵, Jeanne Amiel⁶, Séverine Audebert⁷, Clarisse Baumann-Morel⁸, Patricia Blanchet³, Eric Bieth⁹, Marie Brechard¹⁰, Tiffany Busa¹¹, Patrick Calvas⁹, Yline Capri⁸, François Cartault¹², Nicolas Chassaing⁹, Vidrica Ciorca¹³, Christine Coubes³, Albert David¹⁴, Anne-Lise Delezoide¹⁵, Delphine Dupin-Deguine⁹, Salima El Chehadeh¹⁶, Laurence Faivre¹⁶, Fabienne Giuliano¹⁷, Alice Goldenberg¹⁸, Bertrand Isidor¹⁴, Marie-Line Jacquemont¹⁹, Sophie Julia⁹, Josseline Kaplan⁶, Didier Lacombe²⁰, Marine Lebrun²¹, Sandrine Marlin²², Dominique Martin-Coignard²³, Jelena Martinovic²⁴, Alice Masurel¹⁶, Judith Melki²⁵, Monique Mozelle-Nivoix²⁶, Karine Nguyen¹¹, Sylvie Odent²⁷, Nicole Philip¹¹, Lucile Pinson³, Ghislaine Plessis²⁸, Chloé Quélin²⁷, Elise Shaeffer⁴, Sabine Sigaudy¹¹, Christel Thauvin¹⁶, Marianne Till²⁹, Renaud Touraine²¹, Jacqueline Vigneron³⁰, Geneviève Baujat⁶, Valérie Cormier-Daire⁶, Martine Le Merrer⁶, David Geneviève^{3,2,31} and Isabelle Toutou^{1,2,31}

Heterozygous *COL2A1* variants cause a wide spectrum of skeletal dysplasia termed type II collagenopathies. We assessed the impact of this gene in our French series. A decision tree was applied to select 136 probands (71 Stickler cases, 21 Spondyloepiphyseal dysplasia congenita cases, 11 Kniest dysplasia cases, and 34 other dysplasia cases) before molecular diagnosis by Sanger sequencing. We identified 66 different variants among the 71 positive patients. Among those patients, 18 belonged to multiplex families and 53 were sporadic. Most variants (38/44, 86%) were located in the triple helical domain of the collagen chain and glycine substitutions were mainly observed in severe phenotypes, whereas arginine to cysteine changes were more often encountered in moderate phenotypes. This series of skeletal dysplasia is one of the largest reported so far, adding 44 novel variants (15%) to published data. We have confirmed that about half of our Stickler patients (46%) carried a *COL2A1* variant, and that the molecular spectrum was different across the phenotypes. To further address the question of genotype–phenotype correlation, we plan to screen our patients for other candidate genes using a targeted next-generation sequencing approach.

European Journal of Human Genetics (2016) 24, 992–1000; doi:10.1038/ejhg.2015.250; published online 2 December 2015

INTRODUCTION

Collagen, type II, alpha 1 is the major collagen type synthesized by chondrocytes and the adult vitreous. Type II collagenopathies include a wide variety of skeletal dysplasia ranging from lethal disorders, such as achondrogenesis, type II or hypochondrogenesis (MIM#200610), to adult early onset osteoarthritis at the milder end of the spectrum. Stickler syndrome type I, STL1 (MIM#108300) and Stickler syndrome type I nonsyndromic predominantly ocular (MIM#609508) are the most frequent forms of type II collagenopathies. Stickler syndrome

has an estimated incidence ranging from 1 in 7500 to 1 in 9000 births (<http://ghr.nlm.nih.gov/condition/stickler-syndrome>). Stickler syndrome is characterized by the association of spondyloepiphyseal dysplasia, joint laxity, myopia with congenital vitreous anomalies, and the risk of retinal detachment. These are in addition to conductive and sensorineural progressive hearing loss occurring as early as in the first year of life.

Molecular defects in the *COL2A1* gene (MIM#108300), which encodes the alpha 1 chain of procollagen type II, result in skeletal,

¹Laboratoire de génétique des maladies rares et auto-inflammatoires, CHRU, Montpellier, France; ²Génétique des Maladies Auto-inflammatoires et des Ostéo-arthropathies chroniques, INSERM U1183, Montpellier, France; ³Département de Génétique Médicale, Centre de référence des anomalies du développement, Centre de compétence des Maladies Osseuses Constitutionnelles, CHRU, Montpellier, France; ⁴Génétique Médicale, Hôpital Hautepierre, Strasbourg, France; ⁵Réanimation pédiatrique, CHU Félix Guyon, Saint-Denis, La Réunion, France; ⁶Département de Génétique et INSERM U781, Université Paris Descartes-Sorbonne Paris Cité, Fondation Imagine, Hôpital Necker-Enfants malades, AP-HP, Paris, France; ⁷Pédiatrie et Génétique Médicale, CHU de Brest - Hôpital Auguste Morvan, Brest, France; ⁸Département de Génétique, Hôpital Robert Debré, Paris, France; ⁹Département de Génétique Médicale, institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France; ¹⁰Unité de consultations externes, Hôpital Saint Joseph, Marseille, France; ¹¹Unité de Génétique Clinique, Hôpital d'Enfants de la Timone, Marseille, France; ¹²Service de Génétique, CHU Félix Guyon, Saint-Denis, La Réunion, France; ¹³Service de Génétique, CHU de Nancy, Nancy, France; ¹⁴Génétique Médicale, CHU, Nantes, France; ¹⁵Service de Biologie du Développement, Hôpital Robert Debré, Paris, France; ¹⁶Centre de Génétique, CHU Dijon - Hôpital d'Enfants, Dijon, France; ¹⁷Département de Génétique Médicale, CHU de Nice - Hôpital de l'Archet II, Nice, France; ¹⁸Unité de Génétique Clinique, CHU de Rouen - Hôpital Charles Nicolle, Rouen, France; ¹⁹Génétique Médicale, CHU de la Réunion, Saint Pierre, La Réunion, France; ²⁰Département de Génétique Médicale, Groupe Hospitalier Pellegrin, Bordeaux, France; ²¹Génétique Clinique, Chromosomique et Moléculaire, CHU Hôpital Nord, St Pirest en Jarez, France; ²²Génétique et Embryologie Médicales, Hôpital Armand Trousseau, Paris, France; ²³Génétique Médicale et Cytogénétique, Centre Hospitalier Le Mans, Le Mans, France; ²⁴Unité de Fœtopathologie, Hôpital Antoine Béchère, Paris, France; ²⁵Pôle Neurosciences Tête et Cou (NTC), GHU Paris-Sud - Hôpital de Bicêtre, Le Kremlin Bicêtre, France; ²⁶Unité de génétique - Cytogénétique CHU de Troyes, Troyes, France; ²⁷Service de Génétique Clinique, numéro 9, CHU, Rennes, France; ²⁸Génétique Médicale, CHU Caen - Hôpital Clémenceau, Caen, France; ²⁹Service de Cytogénétique Constitutionnelle, Groupement Hospitalier Est - Hôpitaux de Lyon, Bron, France; ³⁰Génétique clinique Néonatalogie, Maternité Régionale, Nancy, France; ³¹Université de Montpellier, Montpellier, France

*Correspondence: Dr M Barat-Houari, Laboratoire des maladies rares et auto-inflammatoires, CHRU Montpellier, Hôpital A. de Villeneuve, 371, avenue du Doyen Gaston Giraud, Montpellier, Montpellier Cedex 5 34295, France. Tel: +33 4 67 33 61 52; Fax: +33 4 67 33 68 68; E-mail: mouna.barat@inserm.fr

Received 30 January 2015; revised 21 August 2015; accepted 29 October 2015; published online 2 December 2015

orofacial, and ocular disorders. These dominantly inherited diseases are associated with various *COL2A1* variants that include missense, nonsense, small indels or large deletions.^{1,2} The identification of the causative variant in the *COL2A1* gene is essential for establishing the early management of at-risk individuals to propose an accurate assessment of the risks of recurrence in siblings and possibly a prenatal diagnosis.

In 2011, our laboratories developed the molecular screening of the *COL2A1* gene and became the managers of a database specific for this gene at <http://databases.lovd.nl/shared/genes/COL2A1>, which belongs to the LOVD (Leiden Open Variation Database) project. Most of the related published studies are focused on variants identified in Stickler patients. In a recent series of 188 Stickler patients, more than half ($N=100$) were found to harbor a variant in the *COL2A1* gene.¹ However, large series of the other phenotypes associated with variants in this gene have never been reported. In the present study, we describe the molecular spectrum of a total of 136 probands referred to for type II collagenopathies.

MATERIALS AND METHODS

Clinical assessment

All patients referred to our laboratories (Laboratoire de génétique des maladies rares et auto-inflammatoires, CHRU, Montpellier, France) for suspected type II collagenopathy were assessed by a local expert clinician, Professor David Geneviève (DG), the Coordinator of the competence Centre of rare diseases for skeletal dysplasia for the South of France at Montpellier, before molecular screening of the *COL2A1* gene. Demographic, clinical and radiographic data were collected from probands using a specific questionnaire available online at <http://umai.chu-montpellier.fr/diag2.html>. DNA or blood samples were requested from all 136 probands and relevant relatives if available (Figure 1). Informed consent was obtained from each participant before the genetic analysis.

Point variant screening and validation

Genomic DNA was isolated from peripheral EDTA anti-coagulated whole blood using QIAamp DNA Blood Kits (Qiagen, Valencia, CA, USA). Two sets of primer pairs (sequences available upon request) were designed for the *COL2A1* gene (NG_008072.1) using the Primer-Blast software (<http://www.ncbi.nlm.nih.gov/tools/primer-blast/>). Universal M13 tags were added at the

5' ends of each primer. Polymerase chain reactions (PCRs) were performed with the Promega PCR Master Mix according to the manufacturer's protocol (Promega, Madison, WI, USA). The entire coding sequence and intronic boundaries were screened for variants by direct sequencing of two PCR products using the BigDye Terminator v3.1 Cycle Sequencing Kit and M13 primers, followed by electrophoresis of the amplicons on an ABI 3100XL Genetic Analyzer according to the manufacturer's recommendations (Applied Biosystems, Foster City, CA, USA). The obtained sequences were aligned against the *COL2A1* gene reference sequences from NCBI (NG_008072.1 and NM_001844.4) using the SeqScape software.

When a putative disease-causing variant was identified, we performed parental analysis when possible to evaluate segregation and *de novo* occurrence, checked the variant frequency in healthy individuals from public databases (1000 Genomes, Exome Variant Server NHLBI GO Exome Sequencing Project, dbSNP), and the variant pathogenicity using *in silico* predictive tools (Polyphen-2: <http://genetics.bwh.harvard.edu/pph2>, SIFT: <http://sift.bii.a-star.edu.sg>, MutationTaster: <http://www.mutationtaster.org/> and Human Splicing Finder: <http://www.umd.be/HSF3/>).

Rearrangement screening by MLPA and quantitative PCR confirmation

Multiplex Ligation-dependent Probe Amplification (MLPA) was performed according to the manufacturer's recommendations (MRC Holland, Amsterdam, The Netherlands). When Sanger sequencing identified no point *COL2A1* variant, patients' DNA were analyzed using the probe set for *COL2A1* (SALSA MLPA kit 214).

Deletions and duplications detected by MLPA were then confirmed with a qPCR assay using specific primers designed to produce amplicons ranging from 100 to 400 bp on a LightCycler 480 instrument (Roche diagnostics, Meylan, France), as previously described.³ To specify the extent of the whole gene deletion, we used a CytoScanHD array from Affymetrix, according to the supplier's instructions.

RESULTS

Phenotype distribution

Clinical charts from the patients referred for possible type II collagenopathy were reviewed and ascertained by our clinical referral (DG). Among them, 136 probands showed the clinical and radiological features of type II collagenopathies. Almost all the

Figure 1 Workflow showing the different steps and subjects enrolled in our study.

Table 1 COL2A1 variants in 71 French positive patients suffering from skeletal dysplasia

Variant type	Localization	cDNA change	Protein change	Variant effect	Phenotype	LOVD individual ID	Bioinformatics analyses				Reference
							PolyPhen-2	SIFT	Taster	HSF variation	
Substitution	Exon 1	c.70C>T	p.(Gln24*)	Premature stop codon	Kniest dysplasia	24565	Probably damaging	Damaging	Disease causing		This study
Substitution	Exon 6	c.398C>A	p.(Pro133His)	Missense	Stickler type 1	24871	Probably damaging	Damaging			This study
Substitution	Exon 6	c.409C>T	p.(Arg137Cys)	Missense	Achondrogenesis	24895	Probably damaging	Damaging			This study
Substitution	Exon 9	c.638G>T	p.(Gly213Val)	Missense	Stickler type 1	38419					Kannu <i>et al.</i> ²⁶
Substitution	Exon 9	c.647G>A	p.(Gly216Asp)	Missense	Stickler type 1	24538					Hoornaert <i>et al.</i> ¹
Substitution	Exon 10	c.692G>A	p.(Gly231Asp)	Missense	Stickler type 1	24545	Probably damaging	Damaging			This study
Substitution	Exon 16	c.1018G>A	p.(Ala340Thr)	Missense	Stickler type 1	24795	Possibly damaging	Damaging			This study
Substitution	Exon 17	c.1034G>A	p.(Gly345Asp)	Missense	SEMD Strudwick type	24563	Probably damaging	Damaging			This study
Substitution	Exon 19	c.1196G>T	p.(Gly399Val)	Missense	Kniest dysplasia	24870	Probably damaging	Damaging			This study
Substitution	Exon 19	c.1214G>A	p.(Gly405Asp)	Missense	SEDC	24541					Meredith <i>et al.</i> ²⁷
Substitution	Exon 20	c.1259G>A	p.(Gly420Glu)	Missense	SEDC	24807	Probably damaging	Damaging			This study
Substitution	Exon 21	c.1300C>T	p.(Pro434Ser)	Missense	Kniest dysplasia	24799	Probably damaging	Damaging			This study
Substitution	Exon 21	c.1349G>A	p.(Gly450Asp)	Missense	Achondrogenesis	24885	Probably damaging	Damaging			This study
Substitution	Exon 22	c.1373C>T	p.(Pro458Leu)	Missense	SEDC	24873	Probably damaging	Damaging			This study
Substitution	Exon 23	c.1466G>A	p.(Gly489Asp)	Missense	Stickler type 1	24867	Probably damaging	Damaging			This study
Substitution	Exon 23	c.1519G>A	p.(Gly507Arg)	Missense	SEMD Strudwick type	24537	Probably damaging	Damaging			This study
Substitution	Exon 23	c.1484G>A	p.(Gly495Glu)	Missense	SEDC	24881	Probably damaging	Damaging			This study
Substitution	Exon 23	c.1510G>A	p.(Gly504Ser)	Missense	SEDC	24544					Nishimura <i>et al.</i> ⁶
Substitution	Exon 24	c.1537G>A	p.(Gly513Ser)	Missense	Hypochondrogenesis	24811					Mortier <i>et al.</i> ⁴
Substitution	Exon 25	c.1648C>T	p.(Arg550Cys)	Missense	EO-osteoarthritis	24896	Probably damaging	Damaging			This study
Substitution	Exon 26	c.1681G>A	p.(Gly561Ser)	Missense	SEDC	24863	Probably damaging	Damaging			This study
Substitution	Exon 27	c.1772G>A	p.(Gly591Asp)	Missense	Achondrogenesis	24802	Probably damaging	Damaging			This study
Substitution	Exon 32	c.2059G>C	p.(Gly687Arg)	Missense	SEDC	24555	Probably damaging	Damaging			This study
Substitution	Exon 32	c.2059G>A	p.(Gly687Ser)	Missense	SEDC	24866	Probably damaging	Damaging			This study
Substitution	Exon 33	c.2155C>T	p.(Arg719Cys)	Missense	EO-osteoarthritis	24886					Ala-Kokko <i>et al.</i> ¹⁰
Substitution	Exon 35	c.2353C>T	p.(Arg785*)	Premature stop codon	Stickler type 1	24547					Richards <i>et al.</i> ²⁸
Substitution	Exon 37	c.2437G>A	p.(Gly813Arg)	Missense	SEDC	24539	Probably damaging	Damaging			Hoornaert <i>et al.</i> ¹
Substitution	Exon 38	c.2465G>A	p.(Gly822Asp)	Missense	Achondrogenesis	24812	Probably damaging	Damaging			This study
Substitution	Exon 38	c.2491G>A	p.(Gly831Arg)	Missense	SEDC	24561	Probably damaging	Damaging			This study
Substitution	Exon 40	c.2659C>T	p.(Arg887*)	Premature stop codon	Stickler type 1	24880					Hoornaert <i>et al.</i> ¹
Substitution	Exon 41	c.2710C>T	p.(Arg904Cys)	Missense	Stickler type 1	24800					Richards <i>et al.</i> ¹³
Substitution	Exon 41	c.2710C>T	p.(Arg904Cys)	Missense	Kniest dysplasia	24809					Richards <i>et al.</i> ¹³
Substitution	Exon 42	c.2735G>A	p.(Gly912Asp)	Missense	SEDC	24853	Probably damaging	Damaging			This study
Substitution	Exon 42	c.2794C>T	p.(Arg932*)	Premature stop codon	Stickler type 1	24798					Ahmad NN, <i>et al.</i> ²⁹
Substitution	Exon 42	c.2794C>T	p.(Arg932*)	Premature stop codon	Stickler type 1	24813					Liberfarb <i>et al.</i> ²³
Substitution	Exon 43	c.2965C>T	p.(Arg989Cys)	Missense	SEMD Strudwick type	24562					Richards <i>et al.</i> ²⁸
Substitution	Exon 44	c.3106C>T	p.(Arg1036*)	Premature stop codon	Stickler type 1	24551					Ahmad <i>et al.</i> ²⁹
Substitution	Exon 44	c.3106C>T	p.(Arg1036*)	Premature stop codon	Stickler type 1	24553					Liberfarb <i>et al.</i> ²³
Substitution	Exon 44	c.3106C>T	p.(Arg1036*)	Premature stop codon	Stickler type 1	24874					Richards <i>et al.</i> ²⁸
Substitution	Exon 44	c.3106C>T	p.(Arg1036*)	Premature stop codon	Stickler type 1	24874					Chan <i>et al.</i> ¹⁵
Substitution	Exon 46	c.3265G>A	p.(Gly1089Arg)	Missense	SEMD Strudwick type	24535	Probably damaging	Damaging			Hintze <i>et al.</i> ³⁰
Substitution	Exon 47	c.3274G>A	p.(Gly1092Ser)	Missense	SEDC	24852	Probably damaging	Damaging			Hoornaert <i>et al.</i> ¹
Substitution	Exon 48	c.3383G>T	p.(Gly1128Val)	Missense	Stickler type 1	24829					Richards <i>et al.</i> ¹³
Substitution	Exon 48	c.3328G>A	p.(Gly1110Ser)	Missense	SEDC	38483					Richards <i>et al.</i> ¹³
Substitution	Exon 49	c.3472G>A	p.(Gly1158Ser)	Missense	SEDC	24543	Probably damaging	Damaging			Hoornaert <i>et al.</i> ¹
Substitution	Exon 49	c.3472G>A	p.(Gly1158Ser)	Missense	SEDC	24543					Richards <i>et al.</i> ¹³

Table 1 (Continued)

Variant type	Localization	cDNA change	Protein change	Variant effect	Phenotype	LOVD individual ID	Bioinformatics analyses			Reference
							Polyphen-2	SIFT	Mutation Taster	HSF variation
Substitution	Exon 49	c.3455G>A	p.(Gly1152Asp)	Missense	SEDC	24564				Zhang <i>et al.</i> ¹⁷
Substitution	Exon 50	c.3589G>A	p.(Gly1197Ser)	Missense	SEMD Strudwick type	24882				Chan and Cole ³²
Substitution	Exon 50	c.3589G>A	p.(Gly1197Ser)	Missense	SEMD Strudwick type	24897				Chan and Cole ³²
Substitution	Exon 50	c.3574C>T	p.(Arg1192*)	Premature stop codon	Stickler type 1	24850				Zechi-Ceide <i>et al.</i> ^{1,33}
Substitution	Exon 53	c.4316C>T	p.(Thr1439Met)	Missense	Kniest dysplasia	24559				Hoornaert <i>et al.</i> ¹
Substitution	Exon 54	c.4405G>T	p.(Asp1469Tyr)	Missense	SEMD Strudwick type	24856	Probably damaging	Damaging		Unger <i>et al.</i> ³⁴
Substitution	Intron 10	c.709-2A>G	p.?	RNA processing	SEMD Strudwick type	24849				This study
Substitution	Intron 21	c.1366-2A>T	p.?	RNA processing	Stickler type 1	24859				Miyamoto <i>et al.</i> ²⁴
Substitution	Intron 21	c.1365+1G>C	p.?	RNA processing	Kniest dysplasia	24858				This study
Substitution	Intron 31	c.2049+1G>A	p.?	RNA processing	Stickler type 1	24542				This study
Substitution	Intron 33	c.2193+2T>C	p.?	RNA processing	Stickler type 1	24891				Hoornaert <i>et al.</i> ¹
Substitution	Intron 35	c.2355+4A>C	p.?	RNA processing	Stickler type 1	24876				This study
Small deletion	Intron 52	c.4074+2_4074+3delTTG	p.?	RNA processing	Stickler type 1	24546				This study
Small deletion	Exon 3	c.294delG	p.(Gln99Asnfs*18)	Frameshift	Stickler type 1	24805	Disease causing			This study
Small deletion	Exon 15	c.941delC	p.(Pro314Argfs*315)	Frameshift	Stickler type 1	24805	Disease causing			This study
Small deletion	Exon 18	c.1095delT	p.(Gly366Alafs*263)	Frameshift	Stickler type 1	24789	Disease causing			This study
Small deletion	Exon 25	c.1674delA	p.(Ala559Profs*70)	Frameshift	Stickler type 1	24862	Disease causing			This study
Small deletion	Exon 42	c.2858delC	p.(Pro953Leufs*75)	Frameshift	Stickler type 1	24806	Disease causing			This study
Small deletion	Exon 44	c.3012delC	p.(Gly1005Alafs*23)	Frameshift	Stickler type 1	24860	Disease causing			This study
Small deletion	Exon 45	c.3138delT	p.(Gly1047Alafs*83)	Frameshift	Stickler type 1	24854				Hoornaert <i>et al.</i> ¹
Small deletion	Exon 51	c.3778_3779del	p.(Lys1260Valfs*7)	Frameshift	Stickler type 1	24892				Richards <i>et al.</i> ¹³
Small duplication	Exon 22	c.1399_1400dupCA	p.(Gln467Hisfs*163)	Frameshift	Stickler type 1	24794	Disease causing			This study
Small duplication	Exon 40	c.2678dupC	p.(Ala895Serfs*49)	Frameshift	Kniest dysplasia	24556				This study
Small duplication	Exon 44	c.3023dupG	p.(Ala1009Cysts*25)	Frameshift	Stickler type 1	24803				Hoornaert <i>et al.</i> ¹
Large deletion	All gene	c.(?_1)_(*_?)del	p.0	No protein	Stickler type 1	24869				This study
Large deletion	Exon 41-46	c.2745_3221del	p.(Pro916_Gly1074del)	Truncated protein	Achondrogenesis	24810				This study
Large deletion	Intron 1-16	c.85+1360_1023+555del	p.(Gln29Argfs*35)	Frameshift	Stickler type 1	24872				This study

Abbreviations: EO, early onset; HSF, Human Splicing Finder; LOVD, Leiden Open Variation Database; SEMD, Strudwick: Spondyloepiphyseal dysplasia congenita; SEDM, Strudwick: Spondyloepiphyseal dysplasia Strudwick type.

COL2A1-related skeletal disorders were represented and probands were classified as summarized in Table 1. About half of our patients had Stickler syndrome.

Variant distribution and type

We analyzed the entire coding sequence of the *COL2A1* gene and its intronic boundaries, identifying at least one variant in 71 (52%) of our 136 probands (Figure 1). We observed variants in 8 of 9 (89%) Spondyloepimetaphyseal dysplasia Strudwick type (SEMDSTWK) cases, 15 of 21 (71%) Spondylo epiphyseal dysplasia congenita cases (SEDC), 6 of 9 (67%) of the achondrogenesis, type II or hypochondrogenesis cases, 7 of 11 (64%) of the Kniest dysplasia cases, 33 of 71 (46%) of the Stickler patients, and 2 of 5 (40%) of the early onset osteoarthritis (Figure 2a).

The 71 positive probands displayed a total of 66 different variants (Table 1 and Figure 2b). Missense variants were the most frequently observed (58%), including 28 glycine substitutions within a Gly-X-Y repeat. Patients in whom we did not detect point variation by Sanger sequencing were further assessed for gene rearrangement that revealed, in three cases, deletions hereafter termed 'large deletions'.

Novel variants

Among the 66 different variants, 44 were novel (Table 1) and distributed throughout the gene; 38 of 44 (86%) of these are mainly located in the triple helical domain of the procollagen $\alpha 1$ (II)-chain (Figure 3). These 44 novel variants included 26 missense variants and three large deletions. All but one p.(Ala340Thr), c.1018G>A, which was also identified in an unaffected parent) were predicted as likely to be deleterious using the PolyPhen-2 and Sift online programs (<http://genetics.bwh.harvard.edu/pph2/> and <http://sift.jcvi.org/>). Interestingly, in a Stickler family, the p.(Pro314Argfs*315) variant carried by the proband was inherited from a mosaic father (Table 1).

Attempts to genotype/phenotype correlations

When we plotted the variant type against the patient's phenotype, we noticed that the molecular spectrum was different across the diseases. All variant types were observed in Stickler syndrome, whereas only missense variants were observed in SEDC (Figure 2c).

Five arginine to cysteine substitutions were identified in phenotypes with various severities (Table 1). p.(Arg550Cys), c.1648C>T, and p.(Arg719Cys), c.2155C>T were found in two of the five early onset osteoarthritis cases, p.(Arg989Cys), c.2965C>T was found in one Strudwick case, p.(Arg904Cys), c.2710C>T was found in one Stickler case and one Kniest case, and p.(Arg137Cys), c.409C>T was found in a fetus with achondrogenesis, type II. Among the other novel missense variants, we identified three proline substitutions within the Gly-X-Y repeat: p.(Pro133His), c.398C>A was carried by a Stickler patient and her affected mother, p.(Pro434Ser), c.1300C>T was identified in a Kniest patient inherited from his asymptomatic father, and a homozygous variant p.(Pro458Leu), c.1373C>T was found in a SEDC case, inherited from both parents (Table 1).

Among the seven splice variants putatively affecting RNA processing, five were identified in Stickler patients and the two others were identified in a SEMD Strudwick patient and a Kniest patient.

Ten of 11 frameshift variants resulting from small deletions or duplications were identified in Stickler patients. One frameshift variant, p.(Ala895Serfs*49), c.2678dupC, was carried by a Kniest patient.

We also identified three large deletions in two of the most extreme phenotypes, namely a 1364-bp in-frame deletion spanning exons 42 to

Figure 2 (a) Variant distribution according to the patients' phenotype. Achondrogenesis, type II or hypochondrogenesis (MIM#200610), Czech dysplasia (MIM#609162), Kniest dysplasia (MIM#156550), SEMD Strudwick type (MIM#184250), SpondyloEpiphyseal Dysplasia Congenita (MIM#183900), Stickler type 1 (MIM#108300; 609508). (b) Variant distribution among patients according to the type and effect of the variant. (c) Distribution of the variant type and effect according to the patients' phenotype.

46, p.(Pro916_Gly1074del), c.2745_3221del, in a patient with achondrogenesis, type II, a frameshift deletion spanning introns 1 to 16, p.(Gln29Argfs*35), c.85+1360_1023+555del, and a deletion of the entire gene, p.0, c.(?-181)(*442-?)del, in two patients with Stickler syndrome (Table 1).

Variant segregation analysis

Our series included 71 positive cases, among which 53 were sporadic and 18 were from multiplex families (with more than one affected subject; Figure 1).

Figure 3 Distribution of the 44 novel *COL2A1* variants identified in 136 French patients with skeletal dysplasia. I, intron; E, exon; bp, base pair; aa, amino acid; bracket, large deletion; circle, premature stop codon; triangle, small rearrangement; square, glycine missense; diamond, nonglycine missense and asterisk, RNA processing.

Sporadic cases

DNA from both parents was available for 16 sporadic cases. The variant was found to be *a priori de novo* in 15 cases, but was detected in the asymptomatic mother of one achondrogenesis, type II fetus carrying p.(Arg137Cys), c.409C>T (Figure 1).

Familial cases

Among the 42 available relatives of the multiplex families, 15 were asymptomatic and 27 were symptomatic (Figure 1). Of those 27 symptomatic relatives, 26 carried the proband's variant and 1 did not, whereas one of the 15 asymptomatic relatives displayed the proband's variant p.(Ala340Thr), c.1018G>A. These observations support the genetic heterogeneity and the existence of a variant of uncertain significance, respectively. Two representative multiplex families are shown in Figure 4.

DISCUSSION

In this work, we reported the screening for mutants of the *COL2A1* gene in a cohort of 136 probands with clinical and/or radiographic suspicion of a type II collagen disorder. A majority 71 of 136 (52%) of this large cohort were Stickler patients, but 20 of 136 (15%) of the cases were SEDC patients and 5 of 136 (4%) were early onset osteoarthritis patients (Table 1). We identified 66 different *COL2A1* variants spread throughout the *COL2A1* gene. Forty-four of these were novel, which substantially adds to an approximate 300 *COL2A1* variants previously reported in the LOVD database (Table 1) and in the literature.^{1,2}

No variant hotspot was observed in our study, as previously reported.¹ Glycine changes represented 19 of 44 (43%) of the novel variants and were all located in a triple helical region of the collagen 2 (Table 1, Figure 3). The substitution of glycine with bulkier amino

acids in a Gly-X-Y repeat were more often associated with severe phenotypes, such as achondrogenesis, type II or hypochondrogenesis, or with severe short stature phenotypes including Kniest, SEDC and SEMD Strudwick types.⁴⁻⁶ Counter to previous reports, variants in the X or Y positions of the Gly-X-Y motif in the collagen chain did not seem to influence the phenotypes observed in our patients.

Three new proline substitutions were identified in different phenotypes, which were p.(Pro133His), c.398C>A, in Stickler, p.(Pro434Ser), c.1300C>T, in Kniest, and p.(Pro458Leu), c.1373C>T, in SEDC (Table 1). Although the former was located in the X position of the repeat found in the N-terminal region, the two other variants were in the Y position of the repeats found in the triple helical domain. Interestingly, another proline variant located in the Y position p.(Pro986Leu), c.2957C>T was previously shown to segregate with mild SEDC in a three-generation family.⁷ Proline is a highly conserved amino acid in the Y position that contributes to the thermal stability of the triple helix.⁸ Thus, the replacement of the proline with a leucine in the Y position might affect the collagen structure and likely accounts for the short stature observed in dysplasia. However, the pathogenicity of the Pro434Ser substitution remains uncertain, as it was inherited from an asymptomatic parent.

We also report five arginine to cysteine variants, including p.(Arg137Cys), c.409C>T; p.(Arg550Cys), c.1648C>T; p.(Arg719Cys), c.2155C>T; p.(Arg904Cys), c.2710C>T; and p.(Arg989Cys), c.2965C>T (Table 1). The first one, p.(Arg137Cys), c.409C>T, is novel and was identified in a fetus with achondrogenesis, type II. Although it was predicted to be pathogenic by the Polyphen program or damaging by the Sift program, this variant was inherited from the healthy mother. Thus, we propose that it either does not cause the

Figure 4 Pedigree of two representative Stickler multiplex families. (a) Segregation of the p.(Gly366Alafs*263) (c.1095delT) frameshift deletion. (b) Segregation of the intronic c.2355+4A>C variant. Open and dark symbols denote asymptomatic and affected subjects, respectively. The year of birth and the variant status are shown below the symbols.

disease phenotype or is not fully penetrant. In accordance with this hypothesis, it has been reported that unlike the other four variants, p.(Arg137Cys), c.409C>T is not located within the critical triple helical region of the collagen chain, and arginine to cysteine variants never result in lethal conditions.⁹ Sequencing the DNA of this fetus for *DTDST/SLC26A2*, a gene associated with achondrogenesis, type Ib, was also negative. We are currently developing next-generation sequencing using a custom panel of 29 candidate genes that include *GDF5* and *FGFR3* to resolve this case and in the cases in which no *COL2A1* variant was identified. Two other arginine to cysteine variants, p.(Arg550Cys), c.1648C>T and p.(Arg719Cys), c.2155C>T, were observed in two early onset osteoarthritis probands and both segregated with the disease (manuscript in preparation). p.(Arg550Cys), c.1648C>T was novel, but p.(Arg719Cys), c.2155C>T has already been reported once in a patient with osteoarthritis and mild chondrodysplasia.¹⁰ Eyre *et al.*¹¹ have demonstrated that p.(Arg719Cys), c.2155C>T is responsible for a reduction in protein secretion and a limited collagen assembly. The fourth

arginine to cysteine variant, p.(Arg904Cys), c.2710C>T, was found once in a Stickler case and once in a Kniest case, from our series. This variant was already observed in several Stickler cases.^{9,12–14} Finally, p.(Arg989Cys), c.2965C>T was carried by one of our SEMD Strudwick patients, and this variant has been previously reported in several SEDC cases.^{9,15–17} In accordance with the literature, we observed that arginine to cysteine changes were associated with a broad spectrum of diseases, but they were more often encountered in the moderate phenotypes.⁹ Nevertheless, our data confirm that variants such as p.(Arg904Cys), c.2710C>T and p.(Arg989Cys), c.2965C>T, located near the carboxyl terminus of the collagen triple helix were associated with more severe phenotypes.⁹ Arginine to cysteine substitutions introduce novel cysteine residues into the triple helical region, leading to aberrant disulfide bonds between mutant pro-collagen chains.¹ It has also been shown that arginine changes located within a thermostable region such as p.(Arg989Cys), c.2965C>T alter both the assembly of collagen into fibrils and their interaction with other proteins of the cartilage matrix.¹⁸ Hence, these

variants could disturb the thermostability of the protein and exert a dominant negative effect.

We have also identified 11 small deletions and duplications that result in frameshift variants and premature stop codons (PTC; Figure 2c). The p.(Ala895Serfs*49), c.2678dupC variant was carried by one of our Knies patients, but this variant was previously identified in a Stickler case.¹ The p.(Pro314Argfs*315), c.941delC variant was transmitted from a mosaic Stickler father to his affected young daughter who, unlike her father, presented with myopia. One-third (10/33) of our Stickler patients carried PTC variants. Such variants are usually subject to nonsense-mediated decay (NMD), resulting in a loss of function. This mechanism of type II collagen deficiency had often been reported in cases of milder skeletal dysplasia such as Stickler syndrome.¹ In addition to small rearrangements, we also identified three large deletions (Figures 2b and c). The first was a whole gene deletion detected in a patient with a complex phenotype that included Stickler features. This deletion encompassed a wide region of 2.23 Mb on the chromosome 12q13.11 (GRCh37/hg19, chr12:46,316,398..48,547,316), which contained several genes around the COL2A1 gene (data not shown). Deletions of the entire COL2A1 gene and its boundaries have been previously published.^{19–22} The second large (10,554 bp) deletion, p.(Gln29Argfs*35), c.85+1360_1023+555del, was identified in a Stickler proband and his affected father. Both patients displayed severe myopia, and the proband also had bilateral retinal detachment and skeletal anomalies. Thus, the phenotypic differences between the proband and his father suggest an intra-familial variance in clinical expression, suggesting the involvement of modifiers.²³ These two deletions, which were both identified in Stickler cases, were also predicted to be subjected to NMD like the smaller rearrangement described above and would result in a haploinsufficiency.¹⁹ The third large deletion was an in-frame deletion p.(Pro916_Gly1074del), c.2745_3221del, that was expected to result in a shortened peptide lacking 159 amino acids that would exert a dominant negative effect on the 'healthy' component of the trimeric collagen. This hypothesis might account for the severe phenotype observed in this lethal achondrogenesis, type II case.

Splice site variants potentially lead to an abnormal RNA processing that could result in out-of-frame insertions or deletions, creating PTC subjected to NMD. The underlying pathogenic mechanism is therefore a loss of function often associated with mild phenotypes such as Stickler syndrome.¹ Consistently, five of the seven RNA-processing variants we reported (Table 1) were all identified in Stickler cases. These were c.1366-2A>T, c.2049+1G>A, c.2193+2T>C, c.2355+4A>C, and c.4074+2_4074+3delTG. Moreover, c.2355+4A>C segregated in one multiplex Stickler family (Figure 4). The sixth c.1365+1G>C splice variant was carried by a Knies dysplasia patient. Interestingly, the seventh variant c.709-2A>G was carried by a SEMD Strudwick patient. This latter variant was previously reported in an oto-spondylo-megaepiphyseal dysplasia case (OSMED, #215150) and was shown to cause exon skipping, resulting in short transcripts that escaped NMD and led to an in-frame deletion of the triple helical region of the collagen chain.²⁴

Our observations provide a nearly 15% increase in the number of novel variants shown in previous records and illustrate the wide mutability of the COL2A1 gene and its various associated phenotypes.²⁵ Our results also demonstrate the limits of focusing on a single gene during genetic diagnosis given the lack of clear phenotype to genotype correlations. To address this issue, we are now implementing next-generation sequencing approaches in our routine settings.²⁴

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by the CHRU de Montpellier. We thank the probands and their relatives for agreeing to participate in the molecular analysis and American Journal Experts for editing the manuscript for English language.

- 1 Hoornaert KP, Vereecke I, Dewinter C *et al*: Stickler syndrome caused by COL2A1 mutations: genotype-phenotype correlation in a series of 100 patients. *Eur J Hum Genet* 2010; **18**: 872–880.
- 2 Richards AJ, Laidlaw M, Whittaker J *et al*: High efficiency of mutation detection in type 1 stickler syndrome using a two-stage approach: vitreoretinal assessment coupled with exon sequencing for screening COL2A1. *Hum Mutat* 2006; **27**: 696–704.
- 3 Pallares-Ruiz N, Philibert L, Dumont B *et al*: Combined mutation and rearrangement screening by quantitative PCR high-resolution melting: is it relevant for hereditary recurrent Fever genes? *PloS One* 2010; **5**: e14096.
- 4 Mortier GR, Weis M, Nuytinck L *et al*: Report of five novel and one recurrent COL2A1 mutations with analysis of genotype-phenotype correlation in patients with a lethal type II collagen disorder. *J Med Genet* 2000; **37**: 263–271.
- 5 Tysoe C, Saunders J, White L *et al*: A glycine to aspartic acid substitution of COL2A1 in a family with the Strudwick variant of spondyloepimetaphyseal dysplasia. *JIM* 2003; **96**: 663–671.
- 6 Nishimura G, Haga N, Kitoh H *et al*: The phenotypic spectrum of COL2A1 mutations. *Hum Mutat* 2005; **26**: 36–43.
- 7 Mark PR, Torres-Martinez W, Lachman RS, Weaver DD: Association of a p.Pro786Leu variant in COL2A1 with mild spondyloepiphyseal dysplasia congenita in a three-generation family. *Am J Med Genet A* 2011; **155A**: 174–179.
- 8 Berg RA, Prockop DJ: The thermal transition of a non-hydroxylated form of collagen. Evidence for a role for hydroxyproline in stabilizing the triple-helix of collagen. *Biochem Biophys Res Commun* 1973; **52**: 115–120.
- 9 Hoornaert KP, Dewinter C, Vereecke I *et al*: The phenotypic spectrum in patients with arginine to cysteine mutations in the COL2A1 gene. *J Med Genet* 2006; **43**: 406–413.
- 10 Ala-Kokko L, Baldwin CT, Moskowitz RW, Prockop DJ: Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia. *Proc Natl Acad Sci USA* 1990; **87**: 6565–6568.
- 11 Eyre DR, Weis MA, Moskowitz RW: Cartilage expression of a type II collagen mutation in an inherited form of osteoarthritis associated with a mild chondrodysplasia. *J Clin Invest* 1991; **87**: 357–361.
- 12 Ballo R, Beighton PH, Ramesar RS: Stickler-like syndrome due to a dominant negative mutation in the COL2A1 gene. *Am J Med Genet* 1998; **80**: 6–11.
- 13 Richards AJ, McNinch A, Martin H *et al*: Stickler syndrome and the vitreous phenotype: mutations in COL2A1 and COL11A1. *Hum Mutat* 2010; **31**: E1461–E1471.
- 14 Nagendran S, Richards AJ, McNinch A, Sandford RN, Snead MP: Somatic mosaicism and the phenotypic expression of COL2A1 mutations. *Am J Med Genet A* 2012; **158A**: 1204–1207.
- 15 Chan D, Taylor TK, Cole WG: Characterization of an arginine 789 to cysteine substitution in alpha 1 (II) collagen chains of a patient with spondyloepiphyseal dysplasia. *J Biol Chem* 1993; **268**: 15238–15245.
- 16 Donahue LR, Chang B, Mohan S *et al*: A missense mutation in the mouse Col2a1 gene causes spondyloepiphyseal dysplasia congenita, hearing loss, and retinosis. *J Bone Miner Res Off J Am Soc Bone Miner Res* 2003; **18**: 1612–1621.
- 17 Zhang Z, He J-W, Fu W-Z, Zhang C-Q, Zhang Z-L: Identification of three novel mutations in the COL2A1 gene in four unrelated Chinese families with spondyloepiphyseal dysplasia congenita. *Biochem Biophys Res Commun* 2011; **413**: 504–508.
- 18 Steplewski A, Ito H, Rucker E *et al*: Position of single amino acid substitutions in the collagen triple helix determines their effect on structure of collagen fibrils. *J Struct Biol* 2004; **148**: 326–337.
- 19 Van Der Hout AH, Verlind E, Beemer FA, Buys CHCM, Hofstra RMW, Scheffer H: Occurrence of deletion of a COL2A1 allele as the mutation in Stickler syndrome shows that a collagen type II dosage effect underlies this syndrome. *Hum Mutat* 2002; **20**: 236.
- 20 Miyake N, Tonoki H, Gallego M *et al*: Phenotype-genotype correlation in two patients with 12q proximal deletion. *J Hum Genet* 2004; **49**: 282–284.
- 21 Yamanishi T, Nishio J, Miya S *et al*: 12q interstitial deletion with bilateral cleft lip and palate: case report and literature review. *Cleft Palate Craniofac J* 2008; **45**: 325–328.
- 22 Gimelli S, Makrythanasis P, Stouder C, Antonarakis SE, Bottani A, Béna F: A de novo 12q13.11 microdeletion in a patient with severe mental retardation, cleft palate, and high myopia. *Eur J Med Genet* 2011; **54**: 94–96.
- 23 Liberfarb RM, Levy HP, Rose PS *et al*: The Stickler syndrome: genotype/phenotype correlation in 10 families with Stickler syndrome resulting from seven mutations in the type II collagen gene locus COL2A1. *Genet Med* 2003; **5**: 21–27.
- 24 Miyamoto Y, Nakashima E, Hiraoka H, Ohashi H, Ikegawa S: A type II collagen mutation also results in oto-spondylo-megaepiphyseal dysplasia. *Hum Genet* 2005; **118**: 175–178.
- 25 Terhal PA, Nivelsstein RJ, Verver EJ *et al*: A study of the clinical and radiological features in a cohort of 93 patients with a COL2A1 mutation causing spondyloepiphyseal dysplasia congenita or a related phenotype. *Am J Med Genet A* 2015; **167A**: 461–475.

- 26 Kannu P, Irving M, Aftimos S, Savarirayan R: Two novel COL2A1 mutations associated with a Legg-Calvé-Perthes disease-like presentation. *Clin Orthop Relat Res* 2011; **469**: 1785–1790.
- 27 Meredith SP, Richards AJ, Bearcroft P *et al*: Significant ocular findings are a feature of heritable bone dysplasias resulting from defects in type II collagen. *Br J Ophthalmol* 2007; **91**: 1148–1151.
- 28 Richards AJ, Martin S, Yates JR *et al*: COL2A1 exon 2 mutations: relevance to the Stickler and Wagner syndromes. *Br J Ophthalmol* 2000; **84**: 364–371.
- 29 Ahmad NN, Ala-Kokko L, Knowlton RG *et al*: Stop codon in the procollagen II gene (COL2A1) in a family with the Stickler syndrome (arthro-ophthalmopathy). *Proc Natl Acad Sci USA* 1991; **88**: 6624–6627.
- 30 Hintze V, Stepkowski A, Ito H, Jensen DA, Rodeck U, Fertala A: Cells expressing partially unfolded R789C/p.R989C type II procollagen mutant associated with spondyloepiphyseal dysplasia undergo apoptosis. *Hum Mutat* 2008; **29**: 841–851.
- 31 Kuivaniemi H, Tromp G, Prockop DJ: Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. *Hum Mutat* 1997; **9**: 300–315.
- 32 Chan D, Cole WG: Low basal transcription of genes for tissue-specific collagens by fibroblasts and lymphoblastoid cells. Application to the characterization of a glycine 997 to serine substitution in alpha 1(II) collagen chains of a patient with spondyloepiphyseal dysplas. *J Biol Chem* 1991; **266**: 12487–12494.
- 33 Zechi-Ceide RM, Jesus Oliveira NA, Guion-Almeida ML, Antunes LF, Richieri-Costa A, Passos-Bueno MR: Clinical evaluation and COL2A1 gene analysis in 21 Brazilian families with Stickler syndrome: identification of novel mutations, further genotype/phenotype correlation, and its implications for the diagnosis. *Eur J Med Genet* 2008; **51**: 183–196.
- 34 Unger S, Korkko J, Krakow D *et al*: Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal dysplasia congenita. *Am J Med Genet* 2001; **104**: 140–146.